Current in vivo gene therapy approaches face challenges in targeted delivery and safety, limiting their effectiveness in treating a wide range of genetic diseases. Existing gene editing tools may lack the precision needed to address specific mutations without causing off-target effects.

GenEditBio is developing a precision gene editing technology platform for targeted in vivo gene therapies. Their approach utilizes advanced gene editing tools with distinct editing and targeting capabilities to access a broad range of genetic mutations. The platform aims to create safe and effective programmable gene therapy products, overcoming bottlenecks that restrict current in vivo gene editing therapies. By focusing on precision and versatility, GenEditBio seeks to develop durable gene-edited medicines.

Multiple technology platforms designed to tackle bottlenecks restricting in vivo gene editing therapy.

Efficient, versatile, and safe gene editing tools with distinct gene editing and targeting capabilities.

Ability to access a broad range of genetic mutations.

Development of targeted and durable in vivo gene-edited medicines.

The primary target audience includes patients with genetic diseases and the medical community seeking advanced gene therapy solutions.